Drug intelligence / Profile preview

MEDI0618

Development stage: Phase 2
Lead developer: AstraZeneca
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MEDI0618 is a novel human immunoglobulin monoclonal antibody developed by AstraZeneca. It functions as an antagonist of the protease-activated receptor 2 (PAR-2), a receptor implicated in pain and inflammatory pathways. By inhibiting PAR-2, MEDI0618 aims to reduce chronic pain and migraine symptoms. The drug is currently under clinical investigation, with Phase 1 trials completed for chronic pain and ongoing Phase 2 trials for episodic migraine[1][3][4][7]. As a first-in-class PAR-2 antibody, it represents a new approach to targeting neurogenic inflammation and nociceptive signaling in these conditions[4][8].

Other names: Protease-Activated Receptor 2 Antagonist

Targets

PAR2 (Protease-activated receptor 2)

Beyond the preview

Go deeper on MEDI0618.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MEDI0618.

Explore the full profile